Belite Bio, Inc. · NASDAQ:BLTE
Belite Bio — Investor Presentation (2021)
18 slides from Belite Bio's investor presentation, Sep 2, 2021
Slide 1: RBP4 Technology for Macular Degeneration
RBP4 Technology for Macular Degeneration Mission for Vision 2021 Tom Lin, CEO e / [email protected] BELITE BIO / 1
Slide 2: First-in-Class Treatment for Unmet Medical Need
First-in-Class Treatment for Unmet Medical Need Belite Bio is a clinical stage drug development company focused on First-in-Class therapeutics targeting untreatable inherited orphan diseases and age-related metabolic diseases, including atrophic Age-related Macular Degeneration (“dry AMD”), Stargard
Slide 3: The Team
The Team Tom Lin, MMED, PhD, MBA • PhD in Medicine - University of Sydney; Specialization: Neurology & Immunology (CEO) o Treatment Strategies for Autoimmune Neuropathies • Specialist Certificate in Clinical Neuroscience - University of Melbourne; Specialization: Neurology o Neurological Disorders,
Slide 4: The Team
The Team Nathan L. Mata, PhD Irene Wang, PhD, MBA Hao-Yuan Chuang, CFA, MBA, FRM (CSO) (COO) (CFO) • PhD in Neurobiology, MS in Biochemistry, • PhD in Biochemical Sciences, National Taiwan • MBA from Columbia University University of Texas University, Trained at Scripps Research (TSRI), • Served as
Slide 5: Ophthalmology Clinical Advisory Board
Ophthalmology Clinical Advisory Board • Dr. Frank Holz: Chairman of Ophthalmology, • Dr. Robyn Guymer: Professor of Ophthalmology, University of • Dr. Quan Nguyen: Professor of University of Bonn Melbourne & Deputy Director of the Centre for Eye Research Ophthalmology, Stanford University Australia
Slide 6: Executive Summary
Executive Summary Development Strategy • Focus on Stargardt Disease (“STGD”) then Dry AMD Problem of STGD: • Stargardt Disease, inherited form of macular degeneration, has no treatment • Loss of function of ABCA4 causes Vitamin A toxic byproducts (A2E) accumulation in the retina • More than 500 muta
Slide 7: Meet the Unmet Need
MEET THE UNMET NEED LBS Anti-RBP4 Platform 008 for Aging Metabolic Diseases HOPE TO INCURABLE BLINDNESS PHASE III Dry Age-Related Macular Degeneration & Stargardt Disease LBS 009 THE PATH TO METABOLIC DISEASE Non-Alcoholic Fatty Liver Disease & Type 2 PRE-CLINICAL Diabetes BELITE BIO / 7
Slide 8: Hope to Incurable Blindness: Zero Approved Treatments
HOPE TO INCURABLE BLINDESS LBS 008 For Dry Age-Related Macular Degeneration & Stargardt Disease DISCOVERY PRE-CLINICAL KEY OPPORTUNITY Dry AMD MARKET STGD MARKET PHASE I Zero Approved 11M 1 in 10,000 PHASE II PHASE III Treatments MARKET Blind victims suffer from Stargardt Disease Juvenile macular de
Slide 9: Dry AMD number of patients: 9x to Wet AMD
LBS PRODUCT DISEASE PROFILE: 90% AMD ARE “DRY” AMD 008 Dry AMD number of patients: 9x to Wet AMD Wet AMD: Dry AMD: • 10% of AMD Cases • 90% of AMD Cases • $6bn global sales in 2018 • 11mn patients in US alone • 170mn patients globally BELITE BIO / 9
Slide 10: Pathogenesis of Stargardt & Dry AMD
LBS Accumulation of Cytotoxic A2E Due to Ageing, Frequently Exposing to 3C Products and Overuse of eyes 008 Pathogenesis of Stargardt & Dry AMD Normal Retina RPE Changes Rods Die, Cones Spared Cones Die Vision Loss BELITE BIO / 10
Slide 11: Pathogenesis of Stargardt & Dry AMD
LBS Accumulation of Cytotoxic A2E Due to Ageing, Frequently Exposing to 3C Products and Overuse of eyes 008 Pathogenesis of Stargardt & Dry AMD Case Study in the ProgStar study: • The FAF from this STGD patient showed lipofuscin (A2E) is the direct driver for the lesion growth, and can predict the l
Slide 12: MOA: Stargardt & Dry AMD
LBS RBP4 Transports Retinol (Precursor to Cytotoxic A2E) into Retina by Way of Visual Cycle 008 MOA: Stargardt & Dry AMD LBS-008 Induced Enzymes Down-Regulation Retinal Isomers Pigments Rhodopsin 11c-Ral at-Ral STARGARDT PHOTORECEPTORS A2E Gene mutation causes loss of ABCA4 (PR) ABCA4 transporter fu
Slide 13: Reduces A2E Accumulation by 80%
LBS IN ABCA4-/-RDH8-/- MICE, COMPARED TO LBS-008-TREATED 008 Reduces A2E Accumulation by 80% • Daily dosing of 25mg/kg of LBS-008 for 12 weeks. 25.9 • Significant 94.3% and 93.4% serum RBP4 reduction in LBS-008 treated mice at 1- and 12-week time points, respectively. • ~80% A2E reduction in treated
Slide 14: Photoreceptor Degeneration in Abca4-/- Rdh8-/- Mice
IN ABCA4-/-RDH8-/- MICE, COMPARED TO LBS-008-TREATED Photoreceptor Degeneration in Abca4-/- LBS 008 Rdh8-/- Mice • Histological cross-section of retina near optic • Dry AMD or STGD is associated with thinning of the ONL and the loss of nerve, Outer Nuclear Layer (ONL) is the cell layer photoreceptor
Slide 15: US NIH Endorsement
US NIH Endorsement LBS 008 BELITE BIO / 15
Slide 16: UK NIHR Endorsement
UK NIHR Endorsement LBS 008 ▪ 7,948 articles were screened for this Systematic Review on Treatments for dry AMD and Stargardt Disease. Principal findings include: o Research focus should be at earlier stages in both diseases, before vision is impaired. o Most promising treatments for dry AMD and STG
Slide 17: Disclaimer
These materials have been prepared by Belite Bio, Inc (the “Company”) and have not been independently verified. The information contained in these materials does not constitute a recommendation regarding the securities of the Company and/or its affiliates. No representations, warranties or undertaki
Slide 18: RBP4 Technology for Macular Degeneration
RBP4 Technology for Macular Degeneration Mission for Vision Tom Lin, CEO e / [email protected]